ROLE OF BLADDER AND VAGINAL EPITHELIAL CAVEOLAE IN UTIs
膀胱和阴道上皮细胞小窝在尿路感染中的作用
基本信息
- 批准号:7257245
- 负责人:
- 金额:$ 16.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-01 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAntibodiesBacteriaBindingBiological AssayBladderCaveolaeCaveolinsCell membraneCell physiologyCellsCholesterolCollaborationsCytokeratinDataDisruptionElectron MicroscopyEpithelialEpithelial CellsEpitheliumEscherichia coliEstrogensFractionationGanglioside GM1Genitourinary systemGentamicinsGlobosidesGlycolipidsGlycoproteinsGlycosphingolipidsHumanImmune responseKnowledgeLipidsLocalizedMediatingMediationMembraneMicroscopyModelingOrgan ModelOrganismPathogenesisPatternProcessRegulationRoleSignal TransductionSiteSphingomyelinsStaining methodStainsStructureSubcellular FractionsSystemTechniquesTestingTissue EngineeringTissuesToxinTumor SuppressionUrinary tract infectionUropathogenic E. coliVaginaWomancaveolin 1mast cellmicroorganismmonolayerpreventreceptorresearch studyresponsesoluteuptake
项目摘要
Urinary tract infections (UTIs) in women begin with the attachment of infecting microorganisms to vaginal and
subsequently to bladder epithelium. In our prior studies, we utilized primary bladder epithelial cell (BEC) cultures as a
model to define the role and regulation of glycosphingolipids (GSLs) as attachment sites for uropathogenic E. coli, later
extending these studies to a new model of primary vaginal epithelial cell (VEC) cultures. GSLs do not occur randomly
in cell membranes, but instead are organized into specialized membrane domains such as caveolae, characterized by
enrichment in cholesterol, sphingomyelin, glycolipids such as ganglioside GM1, lipid-anchored proteins, and caveolin.
These domains are involved in a wide variety of key cellular functions, including transport of cholesterol,
macromolecular solute transport, tumor suppression, and signal transduction.
Recent evidence demonstrates that caveolae are key molecules in the initial host response to attaching uropathogenic E.
coli in mast cells, mediating the uptake of organisms. We have preliminary data demonstrating that caveolin-1 is present
in primary cultured VEC and BEC monolayers and native vaginal tissue sections, and that native vaginal epithelial cells
contain GM1, a key GSL of caveolae in mast cells and other tissues. The central hypothesis of this proposal is that
caveolae occur in bladder and vaginal epithelium and participate in the initial epithelial responses to attachment
of uropathogenic E. coli. We will pursue the following specific aims: (I) To conclusively demonstrate that caveolae
occur in bladder and vaginal epithelium, we will structurally and biochemically characterize these structures in primary
cultured BEC and VEC, including defining GSLs localized to caveolae in these cells; (2) To address the hypothesis that
caveolae contain key receptor molecules for uropathogenic E. coli, we will determine if caveolin co-localizes with the
globoseries GSLs in primary cultured BEC and VEC and/or with mannosylated glycoproteins that bind Type 1
fimbriated E. coli; (3) To investigate the hypothesis that caveolae mediate uptake of Type 1 fimbriated E. coli into
urogenital epithelium, we will investigate invasion of cultured primary human BEC by this organism, testing for co-
localization of engulfed bacteria with caveolar markers and investigating if disruption of caveolae prevents bacterial
uptake; and (4) using established neo-organ models of bladder and vaginal epithelium, we will demonstrate key findings
from the monolayer systems, such as the presence of caveolae, bacterial invasion, and mediation of this process by
caveolae. These studies will advance knowledge of the role of GSLs and caveolae, fundamental cellular components, in
the pathogenesis ofE. coli UTI.
女性的尿路感染(UTI)开始是感染性微生物附着在阴道上,
随后是膀胱上皮。在我们之前的研究中,我们利用原代膀胱上皮细胞(BEC)培养物作为一种免疫抑制剂。
模型,以确定的作用和调节的鞘糖脂(GSL)作为附着位点的尿路致病性大肠杆菌。大肠杆菌,稍后
将这些研究扩展到原代阴道上皮细胞(VEC)培养的新模型。GSL不是随机发生的
在细胞膜中,而是被组织成专门的膜结构域,如小窝,其特征在于
富含胆固醇、鞘磷脂、糖脂如神经节苷脂GM 1、脂质锚定蛋白和小窝蛋白。
这些结构域参与多种关键细胞功能,包括胆固醇的转运,
大分子溶质转运、肿瘤抑制和信号转导。
最近的证据表明,窖是宿主对尿路致病性大肠杆菌的初始反应的关键分子。
肥大细胞中的大肠杆菌,介导生物体的摄取。我们有初步数据证明存在小窝蛋白-1
在原代培养VEC和BEC单层和天然阴道组织切片以及天然阴道上皮细胞中
含有GM 1,这是肥大细胞和其他组织中小窝的关键GSL。这一提议的核心假设是,
小窝发生在膀胱和阴道上皮中,参与上皮对附着的初始反应
尿致病性E.杆菌我们将追求以下具体目标:(一)最终证明,
发生在膀胱和阴道上皮,我们将在结构和生物化学上表征这些结构,
培养的BEC和VEC,包括定义这些细胞中定位于小窝的GSL;(2)为了解决以下假设,
小窝含有致病性E.大肠杆菌,我们将确定是否caveolin共定位与
在原代培养的BEC和VEC中的球状系列GSL和/或与结合1型的甘露糖基化糖蛋白
流苏E.(3)探讨Caveolae介导1型菌毛大肠杆菌摄取的假说。大肠杆菌进入
泌尿生殖道上皮,我们将研究这种生物体对培养的原代人BEC的侵袭,检测共-
用小窝标记物定位被吞噬的细菌,并研究小窝的破坏是否阻止细菌
摄取;(4)使用已建立的膀胱和阴道上皮新器官模型,我们将证明关键发现
从单层系统,如小窝的存在,细菌入侵,并介导这一过程,
小窝这些研究将促进对GSL和小窝(基本细胞成分)在以下方面作用的认识:
对E. coli UTI。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ann E Stapleton其他文献
Ann E Stapleton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ann E Stapleton', 18)}}的其他基金
Lactobacillus probiotic for prevention of recurrent UTI
乳酸菌益生菌预防复发性尿路感染
- 批准号:
8528569 - 财政年份:2011
- 资助金额:
$ 16.95万 - 项目类别:
Lactobacillus probiotic for prevention of recurrent UTI
乳酸菌益生菌预防复发性尿路感染
- 批准号:
8332134 - 财政年份:2011
- 资助金额:
$ 16.95万 - 项目类别:
Lactobacillus probiotic for prevention of recurrent UTI
乳酸菌益生菌预防复发性尿路感染
- 批准号:
8706851 - 财政年份:2011
- 资助金额:
$ 16.95万 - 项目类别:
Lactobacillus probiotic for prevention of recurrent UTI
乳酸菌益生菌预防复发性尿路感染
- 批准号:
8108248 - 财政年份:2011
- 资助金额:
$ 16.95万 - 项目类别:
ROLE OF BLADDER AND VAGINAL EPITHELIAL CAVEOLAE IN UTIs
膀胱和阴道上皮细胞小窝在尿路感染中的作用
- 批准号:
6797120 - 财政年份:2003
- 资助金额:
$ 16.95万 - 项目类别:
ROLE OF BLADDER AND VAGINAL EPITHELIAL CAVEOLAE IN UTIs
膀胱和阴道上皮细胞小窝在尿路感染中的作用
- 批准号:
7092010 - 财政年份:2003
- 资助金额:
$ 16.95万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
Fellowship Programs